1193P - LuCaBIS: A burden-of-illness study in patients with Stage IB-IIIA non-small cell lung cancer in France, Germany and the UK

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Non-Small-Cell Lung Cancer, Early Stage
Supportive Care
Bioethics, Legal, and Economic Issues
Non-Small-Cell Lung Cancer, Locally Advanced
Presenter Sarah Danson
Citation Annals of Oncology (2014) 25 (suppl_4): iv409-iv416. 10.1093/annonc/mdu347
Authors S. Danson1, S. Andreas2, C. Chouaid3, O. Siakpere4, L. Benjamin5, R. Ehness6, M. Dramard-Goasdoue5, J. Barth6, M. Price7, S. Wolowacz8, J. Kaye9, I. Kontoudis10
  • 1Department Of Oncology, Weston Park Hospital, S10 2SJ - SHEFFIELD/GB
  • 2Pneumology, Lungenfachklinik Immenhausen, Krs. Kassel and Universitätsmedizin Göttingen, Immenhausen/DE
  • 3Pneumology, CHIC Creteil, Créteil/FR
  • 4Medical, GlaxoSmithKline UK, Middlesex/GB
  • 5Health Economics And Outcomes Research, GlaxoSmithKline France, Marly le Roi/FR
  • 6Medical Hematology/oncology, GlaxoSmithKline GmbH & Co KG, Muenchen/DE
  • 7Surveys And Observational Studies, RTI Health Solutions, Research Triangle Park/US
  • 8Health Economics, RTI Health Solutions, Manchester/GB
  • 9Epidemiology, RTI Health Solutions, Waltham/US
  • 10Itx, GlaxoSmithKline Vaccines, 1330 - Rixensart/BE

Abstract

Aim

Although new adjuvant treatments (ADJ) are being developed for patients (pts) with resected non-small cell lung cancer (NSCLC), the health technology assessment, they will be subject to in many countries, can be limited by the scarcity of real-world data in the specific disease setting. This study aimed to collect such data in France (F), Germany (G), and the United Kingdom (UK) looking at characteristics of pts receiving ADJ (or not), clinical outcomes, resource utilization and costs.

Methods

Pts were age ≥18 years (yrs) with completely resected stage IB-IIIA NSCLC diagnosed from August 2009 to July 2012. Pts were enrolled at clinical sites by a systematic sampling method. Pts could be living or deceased at the time of data collection. Clinical info was abstracted from medical records. All analyses were descriptive.

Results

Data on 831 pts (F: 251; G: 287; UK: 293) were collected through 39 (F: 14; G: 11; UK: 14). Thirty-three percent were age ≤60 yrs, 37% were 61-70 yrs, and 30% were ≥71 yrs; 62% were male. Histology was adenocarcinoma (53%), squamous (38%), large cell (2%), or unspecified (6%). Seventy-two percent had systematic lymph node dissection (F: 96%; G: 90%; UK: 33%). Stages were IB (29%), IIA (22%), IIB (20%), and IIIA (30%). More pts had stages IB or IIA in UK (66%) than in F (39%) or G (44%). Overall, 402 pts (48%) received ADJ (F: 62%; G: 52%; UK: 33%).

Pts Given ADJ (% by Stage)
Stage F G UK Overall
IB 10/58 (17) 12/70 (17) 14/111 (13) 36/239 (15)
IIA 22/39 (56) 34/57 (60) 37/83 (45) 93/179 (52)
IIB 32/46 (70) 39/64 (61) 25/55 (45) 96/165 (58)
IIIA 91/108 (84) 64/96 (67) 22/44 (50) 177/248 (71)

Cisplatin + vinorelbine ADJ was used most frequently (258 pts; 64% of those given ADJ). Common reasons for not using ADJ were: pt declined (13%), comorbidities (12%), surgery complication (8%), or poor performance status (7%).. Median overall survival (OS) was not reached while 25th percentile was 31.2 months (mth) (95%; CI 26.8-36.0 mth). Median disease-free survival (DFS) was 48.0 mth (95%; CI 42.3 mth-not estimable).

Conclusions

ADJ use increased by stage but was used in less than half of pts overall and was used less in the UK than in F or G. It may be possible that a favorable stage distribution in UK is related to less use of systematic lymph node dissection.

Disclosure

S. Danson: Dr Danson reports conflicts of interest from GlaxoSmithKline group of companies, Eli Lilly, Bristol Myers Squibb, Boehringen Ingelheim, AstraZeneca, Onco-NX, Incanthera, Genta, Abraxane, Daiichi-Sankyo and Morphotek; S. Andreas: Dr Andreas discloses honoraria for advisory boards and lectures from Roche, Boerhinger Ingelheim, Pfizer and GlaxoSmithKline group of companies; C. Chouaid: In the past 5 years, Dr Chouaid received fees for attending scientific meetings, speaking, organizing research or consulting from AstraZeneca, BI, Hoffman La Roche, Sanofi Avensis, Lilly, Novartis, Amgen and GlaxoSmithKline group of companies; O. Siakpere: Dr Siakpere is employee of GlaxoSmithKline group of companies; L. Benjamin: Dr Benjamin is employee of GlaxoSmithKline group of companies and holds stock or stock options or restricted shares; R. Ehness: Dr Ehness is employee of GlaxoSmithKline group of companies and holds stock or stock options or restricted shares; M. Dramard-Goasdoue: Dr Dramard-Goasdoue is employee of GlaxoSmithKline group of companies; J. Barth: J. Barth is employee of GlaxoSmithKline group of companies; M. Price: M Price reports funding from GlaxoSmithKline group of companies to his employer, RTI Health Solutions, during the conduct of the study; S. Wolowacz: Dr Wolowacz reports funding from GlaxoSmithKline group of companies to her employer, RTI Health Solutions, during the conduct of the study; J.A. Kaye: Dr Kaye reports funding from GlaxoSmithKline group of companies to his employer, RTI Health Solutions, during the conduct of the study; I. Kontoudis: Dr Kontoudis is employee of GlaxoSmithKline group of companies.